NCT03546361View on ClinicalTrials.gov

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 8, 2019

Primary Completion Date

January 11, 2026

Study Completion Date

January 11, 2027

Conditions

Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8Stage IVB Lung Cancer AJCC v8

Interventions

BIOLOGICAL

Autologous Dendritic Cell-Adenovirus CCL21 Vaccine

Given via CT-guided or bronchoscopic IT injection

BIOLOGICAL

Pembrolizumab

Given IV

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors

collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

LUNGevity Foundation

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT03546361 - CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter